About Foundation Medicine
Foundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. The Company's segment is the business of delivering molecular information about cancer to its customers. Its products provide genomic information about each patient's individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its flagship clinical molecular information products, FoundationOne for solid tumors, and FoundationOne Heme for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma and advanced sarcomas, are genomic profiles designed for use in the routine care of patients with cancer. Its other products include FoundationACT (Assay for Circulating Tumor deoxyribonucleic acid (DNA)), GeneKit, FoundationCORE, FoundationICE and the SmartTrials program.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: FMI
- Previous Close: $24.40
- 50 Day Moving Average: $20.19
- 200 Day Moving Average: $21.69
- 52-Week Range: $13.57 - $27.55
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.90
- P/E Growth: 0.00
- Market Cap: $855.42M
- Outstanding Shares: 35,058,000
- Beta: -0.2
- Net Margins: -84.67%
- Return on Equity: -42.21%
- Return on Assets: -35.70%
Companies Related to Foundation Medicine:
- Current Ratio: 5.04%
- Quick Ratio: 4.74%
What is Foundation Medicine's stock symbol?
Foundation Medicine trades on the NASDAQ under the ticker symbol "FMI."
Where is Foundation Medicine's stock going? Where will Foundation Medicine's stock price be in 2017?
6 equities research analysts have issued 12 month price targets for Foundation Medicine's stock. Their predictions range from $15.00 to $25.00. On average, they anticipate Foundation Medicine's share price to reach $17.50 in the next year.
When will Foundation Medicine announce their earnings?
Foundation Medicine is scheduled to release their next quarterly earnings announcement on Tuesday, February, 21st 2017.
Who owns Foundation Medicine stock?
Foundation Medicine's stock is owned by a number of of institutional and retail investors. Top institutional investors include Discovery Group I LLC (4.55%), ARK Investment Management LLC (0.85%), State Street Corp (0.63%), Baillie Gifford & Co. (0.50%), FMR LLC (0.26%) and Russell Investments Group Ltd. (0.09%). Company insiders that own Foundation Medicine stock include Alexis Borisy, David Daly, Jason Ryan, Krishna Yeshwant, Michael J Pellini, Robert W Hesslein, Roche Holdings Inc, Rock Ventures Lp Third, Steven J Kafka and Vincent A Miller.
Who sold Foundation Medicine stock? Who is selling Foundation Medicine stock?
Foundation Medicine's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC. Company insiders that have sold Foundation Medicine stock in the last year include David Daly, Jason Ryan, Michael J Pellini, Robert W Hesslein, Steven J Kafka and Vincent A Miller.
Who bought Foundation Medicine stock? Who is buying Foundation Medicine stock?
Foundation Medicine's stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Discovery Group I LLC, Russell Investments Group Ltd., Moloney Securities Asset Management LLC, State Street Corp, GSA Capital Partners LLP, Metropolitan Life Insurance Co. NY and Commerzbank Aktiengesellschaft FI. Company insiders that have bought Foundation Medicine stock in the last two years include Michael J Pellini and Roche Holdings Inc.
How do I buy Foundation Medicine stock?
Shares of Foundation Medicine can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Foundation Medicine stock cost?
One share of Foundation Medicine stock can currently be purchased for approximately $24.40.